We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+18.23%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.29B
AUM Growth
+$158M
Cap. Flow
+$36.7M
Cap. Flow %
2.84%
Top 10 Hldgs %
39.6%
Holding
109
New
17
Increased
24
Reduced
36
Closed
22

Top Buys

Rank Stock Value
1
GRFS
Grifois
GRFS
+$36.8M
2
SNY icon
Sanofi
SNY
+$29.7M
3
QDEL icon
QuidelOrtho
QDEL
+$27.8M
4
KRYS icon
Krystal Biotech
KRYS
+$17.5M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$24.3M
2
NRIX icon
Nurix Therapeutics
NRIX
+$22.4M
3
PEN icon
Penumbra
PEN
+$22.2M
4
HUM icon
Humana
HUM
+$16.6M
5
GSK icon
GSK
GSK
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.11%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
76
Insmed
INSM
$28.6B
$2.21M 0.17%
30,272
-72,200
-70% -$5.33M
VRDN icon
77
Viridian Therapeutics
VRDN
$2.61B
$2.16M 0.17%
95,000
-245,000
-72% -$4.01M
ADVM
78
DELISTED
Adverum Biotechnologies
ADVM
$2.02M 0.16%
287,246
+140,000
+95% +$1.02M
CRVO icon
79
CervoMed
CRVO
$26.3M
$1.85M 0.14%
126,614
– –
VCYT icon
80
Veracyte
VCYT
$3.83B
$1.85M 0.14%
+54,303
New +$1.53M
BCYC
81
Bicycle Therapeutics
BCYC
$289M
$1.77M 0.14%
78,315
+54,815
+233% +$1.26M
GSK icon
82
GSK
GSK
$106B
$1.53M 0.12%
37,500
-377,500
-91% -$15.4M
ABVX
83
Abivax
ABVX
$11.5B
$1.44M 0.11%
+125,000
New +$1.5M
OLMA icon
84
Olema Pharmaceuticals
OLMA
$1.06B
$1.24M 0.1%
103,500
-113,000
-52% -$1.44M
WHWK
85
Whitehawk Therapeutics
WHWK
$240M
$686K 0.05%
333,227
– –
IMVT icon
86
Immunovant
IMVT
$8.29B
$276K 0.02%
9,678
-242,222
-96% -$7.14M
IOBT
87
DELISTED
IO Biotech
IOBT
$202K 0.02%
192,670
– –
AVDL
88
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-509,000
Closed -$7.16M
CVRX icon
89
CVRx
CVRX
$77M
– –
-587,098
Closed -$7.04M
EXAS
90
DELISTED
Exact Sciences
EXAS
– –
-91,611
Closed -$3.87M
FATE icon
91
Fate Therapeutics
FATE
$296M
– –
-870,000
Closed -$2.85M
FDMT icon
92
4D Molecular Therapeutics
FDMT
$562M
– –
-108,598
Closed -$2.28M
GMED icon
93
Globus Medical
GMED
$11.2B
– –
-86,000
Closed -$5.89M
HIMS icon
94
Hims & Hers Health
HIMS
$7.07B
– –
-333,000
Closed -$6.72M
HUM icon
95
Humana
HUM
$44.7B
– –
-44,356
Closed -$16.6M
INBX icon
96
Inhibrx
INBX
$1.28B
– –
-88,470
Closed -$1.25M
IRMD icon
97
iRadimed
IRMD
$1.17B
– –
-102,067
Closed -$4.48M
JANX icon
98
Janux Therapeutics
JANX
$980M
– –
-55,500
Closed -$2.32M
JAZZ icon
99
Jazz Pharmaceuticals
JAZZ
$16.7B
– –
-53,935
Closed -$5.76M
MDXG icon
100
MiMedx Group
MDXG
$618M
– –
-82,884
Closed -$574K
1 2 3
4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Soleus Capital Management held 109 positions worth $1.29B, up 14% from $1.13B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Soleus Capital Management's Q3 2024 filing shows 17 new, 24 increased, 36 reduced and 22 closed positions. Its largest new stake was Grifois: 4,521,703 shares worth $40.2M. The largest sale was TG Therapeutics, an estimated $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

  • Soleus Capital Management's largest Q3 2024 buy was Grifois: 4,521,703 shares worth $40.2M.
  • Soleus Capital Management added most to Sanofi in Q3 2024, an estimated $29.7M increase.
  • Soleus Capital Management's biggest Q3 2024 reduction was TG Therapeutics, cutting an estimated $24.3M.
  • Soleus Capital Management fully exited Penumbra in Q3 2024, selling an estimated $22.2M.
  • Soleus Capital Management's ten largest holdings make up 40% of its $1.29B portfolio in Q3 2024.
  • Soleus Capital Management opened 17 new positions and closed 22 in Q3 2024.
  • Soleus Capital Management's portfolio value rose 14% quarter-over-quarter to $1.29B.

Based on Soleus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.